Boehringer Ingelheim and Eli Lilly announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta to include use in combination with insulin in adults with Type 2 Diabetes. The approval means linagliptin is now indicated for use in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. The U.S. FDA approved linagliptin for use as add on to insulin in adults with Type 2 Diabetes in August.
- Pharmaceuticals & Drug Trials
- Eli Lilly
- Boehringer Ingelheim
- the European Commission
- Type 2 Diabetes